Integrative Omics Analysis for Colorectal Cancer and Metastasis
A Prospective Study of Integrative Omics Analysis for Colorectal Cancer and Metastasis
1 other identifier
observational
20
1 country
1
Brief Summary
The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 4, 2022
CompletedFirst Posted
Study publicly available on registry
August 1, 2022
CompletedStudy Start
First participant enrolled
August 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedAugust 1, 2022
July 1, 2022
2.4 years
May 4, 2022
July 29, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
overall survival rate
the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
3 years after surgery
disease free survival rate
the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
3 years after surgery
Secondary Outcomes (3)
Quality of life outcomes evaluation(QLQ-CR38)
0- 2 years after surgery
Quality of life outcomes evaluation(QLQ-C30)
0- 2 years after surgery
R0 resection rate
2 weeks after surgery
Study Arms (1)
colorectal cancer with metastasis
colorectal cancer patients with at least one distant metastasis(liver, lung)
Interventions
Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Eligibility Criteria
All patients with colorectal cancer and metastasis will be enrolled.
You may qualify if:
- colorectal adenocarcinoma by biopsy。
- at least 1 metastasis lesion comfirmed by at least 1 kind of imaging examination (CT, MRI and PET-CT )
You may not qualify if:
- recent diagnosis with other malignancies
- can not tolerate the surgery
- history of serious mental illness
- pregnancy or lactating women
- the researchers believe the patients should not enrolled in
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- fan lilead
Study Sites (1)
Daping hospital
Chongqing, 400042, China
Biospecimen
Colorectal cancer (CRC), adjacent colon, lymph nodes (LN) along colons, metastasis (DM), and adjacent of metastasis ,lymph nodes (LM) along metastasis ,and peripheral blood mononuclear cells (PBMC)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
May 4, 2022
First Posted
August 1, 2022
Study Start
August 1, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2025
Last Updated
August 1, 2022
Record last verified: 2022-07